Specialty drugs may push Sun Pharma's US biz beyond $2 bn by 2025

Betting on its specialty drugs portfolio, analysts expect the revenue from Sun Pharmaceutical Industries’ US business to cross $2 billion by 2025. The Mumbai-based firm is currently working on clinical trials of four specialty drugs.

Specialty medicines are used to treat chronic, complex, and rare diseases. These medicines are typically more expensive than traditional medicines. Also, they differ in terms of the complexity of disease management and their distribution. The share of specialty medicines in overall pharmaceutical spending has been consistently increasing over the past decade, from 22 per cent in 2011 to 39 per cent in 2021. By 2026,